Vildagliptin in clinical practice: a review of literature.
Vildagliptin is the second member of the DPP-IV inhibitor class of drugs licensed for the treatment of type 2 diabetes mellitus (T2DM). The novel action of these drugs has promoted a new outlook in the pathobiology of T2DM. This review undertakes to examine the clinical studies published to date, with the aim of evaluating the position of vildagliptin among the drugs that are now available to treat this common dysmetabolic state.
Banerjee
Moulinath
M
Central Manchester University Hospitals Foundation Trust, Department of Medicine, Manchester, M13 9WL, UK.
Younis
Naveed
N
Soran
Handrean
H
D000218:Adamantane / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007515:Islets of Langerhans / Q000187:drug effects; D009570:Nitriles / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D011759:Pyrrolidines / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D000077597:Vildagliptin
D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D009570:Nitriles; D011759:Pyrrolidines; D000077597:Vildagliptin; D000218:Adamantane